Olesya A. Kharenko, Ph.D. - Publications

2005 Bowling Green State University, Bowling Green, OH, United States 

6/27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2006 Hong J, Kharenko OA, Ogawa MY. Incorporating electron-transfer functionality into synthetic metalloproteins from the bottom-up. Inorganic Chemistry. 45: 9974-84. PMID 17140193 DOI: 10.1021/Ic060222J  0.77
2006 Hong J, Kharenko OA, Fan J, Xie F, Petros AK, Gibney BR, Ogawa MY. Evidence that a miniature CuI metalloprotein undergoes collisional electron transfer in the inverted Marcus region. Angewandte Chemie (International Ed. in English). 45: 6137-40. PMID 16927358 DOI: 10.1002/Anie.200601517  0.778
2006 Ogawa MY, Fan J, Fedorova A, Hong J, Kharenko OA, Kornilova AY, Lasey RC, Xie F. Electron-transfer functionality of synthetic coiled-coil metalloproteins Journal of the Brazilian Chemical Society. 17: 1516-1521. DOI: 10.1590/S0103-50532006000800006  0.612
2006 Ogawa MY, Fan J, Fedorova A, Hong J, Kharenko OA, Kornilova AY, Lasey RC, Xie F. Electron-transfer functionality of synthetic coiled-coil metalloproteins Journal of the Brazilian Chemical Society. 17: 1516-1521. DOI: 10.1590/S0103-50532006000800006  0.597
2005 Kharenko OA, Kennedy DC, Demeler B, Maroney MJ, Ogawa MY. Cu(I) luminescence from the tetranuclear Cu4S4 cofactor of a synthetic 4-helix bundle. Journal of the American Chemical Society. 127: 7678-9. PMID 15913348 DOI: 10.1021/Ja042757M  0.632
2004 Kharenko OA, Ogawa MY. Metal-induced folding of a designed metalloprotein. Journal of Inorganic Biochemistry. 98: 1971-4. PMID 15522423 DOI: 10.1016/J.Jinorgbio.2004.07.015  0.675
Low-probability matches (unlikely to be authored by this person)
2015 Duffy BC, Liu S, Martin GS, Wang R, Hsia MM, Zhao H, Guo C, Ellis M, Quinn JF, Kharenko OA, Norek K, Gesner EM, Young PR, McLure KG, Wagner GS, et al. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design. Bioorganic & Medicinal Chemistry Letters. 25: 2818-23. PMID 26022843 DOI: 10.1016/J.Bmcl.2015.04.107  0.295
2013 Kharenko OA, Choudhary P, Loewen MC. Abscisic acid binds to recombinant Arabidopsis thaliana G-protein coupled receptor-type G-protein 1 in Sacaromycese cerevisiae and in vitro. Plant Physiology and Biochemistry : Ppb. 68: 32-6. PMID 23624020 DOI: 10.1016/J.Plaphy.2013.03.025  0.293
2013 Kharenko OA, Polichuk D, Nelson KM, Abrams SR, Loewen MC. Identification and characterization of interactions between abscisic acid and human heat shock protein 70 family members. Journal of Biochemistry. 154: 383-91. PMID 23975754 DOI: 10.1093/Jb/Mvt067  0.287
2013 Dorosh L, Kharenko OA, Rajagopalan N, Loewen MC, Stepanova M. Molecular mechanisms in the activation of abscisic acid receptor PYR1. Plos Computational Biology. 9: e1003114. PMID 23825939 DOI: 10.1371/Journal.Pcbi.1003114  0.278
2010 Kharenko O, Boyd J, Loewen MC. Functional Characterization of Recombinant Arabidopsis Thaliana Mitochondrial Adenine Nucleotide Translocator 2 Biophysical Journal. 98. DOI: 10.1016/J.Bpj.2009.12.2754  0.272
2018 Kharenko O, Patel RG, Brown SD, Calosing C, White A, Lakshminarasimhan D, Suto RK, Duffy BC, Kitchen DB, McLure KG, Hansen HC, van der Horst EH, Young PR. DESIGN AND CHARACTERIZATION OF NOVEL COVALENT BROMODOMAIN AND EXTRA-TERMINAL DOMAIN (BET) INHIBITORS TARGETING A METHIONINE. Journal of Medicinal Chemistry. PMID 30165024 DOI: 10.1021/Acs.Jmedchem.8B00666  0.271
2017 Kharenko OA, Hansen HC. Novel approaches to targeting BRD4. Drug Discovery Today. Technologies. 24: 19-24. PMID 29233295 DOI: 10.1016/J.Ddtec.2017.10.003  0.265
2016 Kharenko OA, Gesner EM, Patel RG, Norek K, White A, Fontano E, Suto RK, Young PR, McLure KG, Hansen HC. RVX-297- a novel BD2 selective inhibitor of BET bromodomains. Biochemical and Biophysical Research Communications. PMID 27282480 DOI: 10.1016/J.Bbrc.2016.06.021  0.265
2011 Kharenko OA, Boyd J, Nelson KM, Abrams SR, Loewen MC. Identification and characterization of interactions between abscisic acid and mitochondrial adenine nucleotide translocators. The Biochemical Journal. 437: 117-23. PMID 21473740 DOI: 10.1042/Bj20101898  0.245
2013 McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E, Suto RK, Wong NC, Wagner GS, Hansen HC, Young PR. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. Plos One. 8: e83190. PMID 24391744 DOI: 10.1371/Journal.Pone.0083190  0.237
2015 Attwell S, Campeau E, Jahagirdar R, Kharenko O, Norek K, Tsujikawa L, Calosing C, Patel R, Gesner E, Lakhotia S, Hansen H. Abstract C86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies, alone or in combination with several standard of care and targeted therapies Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C86  0.232
2016 Attwell S, Jahagirdar R, Norek K, Calosing C, Tsujikawa L, Kharenko OA, Patel RG, Gesner EM, Corey E, Nguyen HM, Lakhotia S, Hansen HC, Campeau E. Abstract LB-207: Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-207  0.22
2020 Kharenko OA, Patel RG, Calosing C, Horst EHvd. Abstract 1750: Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer Cancer Research. 80: 1750-1750. DOI: 10.1158/1538-7445.Am2020-1750  0.219
2020 Cosín M, Tian T, Oliveros W, Kharenko OA, Horst EHvd, Patel RG, Calosing C, Campeau E, Jahagirdar R, Lakhotia S, Melé M, Palafox M, Arribas J, Oliveira M, Saura C, et al. Abstract 1282: Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer Cancer Research. 80: 1282-1282. DOI: 10.1158/1538-7445.Am2020-1282  0.208
2018 Kharenko O, Patel R, Jahagirdar R, Attwell S, Calosing C, Tsujikawa L, Campeau E, Lakhotia S, Hansen H. Abstract P3-06-07: The BET bromodomain inhibitors ZEN-3694 and ZEN-3309 targets several mechanisms of resistance to endocrine therapies in preclinical models of ER+ breast cancers Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-06-07  0.2
2011 Kharenko OA, Zaharia LI, Giblin M, Čekić V, Taylor DC, Don Palmer C, Abrams SR, Loewen MC. Abscisic acid metabolism and lipid accumulation of a cell suspension culture of Lesquerella fendleri Plant Cell, Tissue and Organ Culture. 105: 415-422. DOI: 10.1007/S11240-010-9881-7  0.2
2013 Campeau E, Jahagirdar R, Wu J, Gesner EM, Kharenko O, Yu R, Attwell S, Hansen HC, Wagner GS, McLure KG, Young PR. Abstract LB-92: RVX-2135 is a novel, orally bioavailable epigenetic BET inhibitor that synergizes with cytarabine and idarubicin to inhibit proliferation of acute myeloid leukemia cells. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-92  0.182
2021 Mélin L, Gesner E, Attwell S, Kharenko OA, van der Horst EH, Hansen HC, Gagnon A. Design and Synthesis of LM146, a Potent Inhibitor of PB1 with an Improved Selectivity Profile over SMARCA2. Acs Omega. 6: 21327-21338. PMID 34471737 DOI: 10.1021/acsomega.1c01555  0.162
2021 Mélin L, Calosing C, Kharenko OA, Hansen HC, Gagnon A. Synthesis of NVS-BPTF-1 and evaluation of its biological activity. Bioorganic & Medicinal Chemistry Letters. 47: 128208. PMID 34146702 DOI: 10.1016/j.bmcl.2021.128208  0.124
2021 Kharenko OA, Patel RG, Calosing C, van der Horst EH. Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer. Cancer Gene Therapy. PMID 34385584 DOI: 10.1038/s41417-021-00375-9  0.08
2022 Tsujikawa LM, Kharenko OA, Stotz SC, Rakai BD, Sarsons CD, Gilham D, Wasiak S, Fu L, Sweeney M, Johansson JO, Wong NCW, Kulikowski E. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 152: 113230. PMID 35687908 DOI: 10.1016/j.biopha.2022.113230  0.072
Hide low-probability matches.